Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.53 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24235568 | 0.88 | FOLH1 (0.58) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL17384176 | 0.86 | FOLH1 (0.60) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL14310838 | 0.84 | FOLH1 (0.72) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL7046532 | 0.83 | GNPAT (0.65) | GNPATFOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL1533825 | 0.82 | FOLH1 (0.69) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL6270974 | 0.82 | FOLH1 (0.69) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL16565941 | 0.81 | GNPAT (0.58) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL21360278 | 0.81 | FOLH1 (0.58) | GNPATFOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL7047615 | 0.81 | GNPAT (0.56) | GNPATFOLH1NAALAD2RIMKLANOD1 | |
| SCHEMBL24208493 | 0.80 | NOD1 (0.52) | GNPATFOLH1NAALAD2RIMKLAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20140213504-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | CERULEAN PHARMA INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058873-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | GNPAT 966/4885FOLH1 164/4885NAALAD2 450/4885 |
| US-20140213504-A1 | Cyclodextrin-Based Polymers for Therapeutic Delivery | IAPP, PRCP, DDOST | GNPAT 966/4885FOLH1 164/4885NAALAD2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.